Table 2

Baseline demographic and clinical characteristics by incident CVD events in the VADT and the ACCORD subcohorts included in these analyses

VADTACCORD
CVD (n = 107)No CVD (n = 338)CVD (n = 135)No CVD (n = 136)
Participants receiving intensive treatment50524751
Age (years)60 ± 8†58 ± 864 ± 664 ± 6
Male sex99967675
Non-Hispanic white72*607268
Prior CVD59§2557§33
BMI (kg/m2)31 ± 531 ± 432 ± 532 ± 5
Diabetes duration (years)13 ± 8‡10 ± 712.7 ± 7.310.5 ± 7
Hemoglobin A1c (% [mmol/mol])9.3 ± 1.3 (79 ± 14)9.5 ± 1.5 (80 ± 17)8.2 ± 0.9 (67 ± 10)8.3 ± 1.0 (67 ± 11)
Cholesterol (mmol/L)
 Total4.8 ± 1.54.7 ± 0.94.5 ± 0.94.7 ± 1.0
 LDL2.8 ± 0.82.7 ± 0.82.4 ± 1.02.7 ± 0.8
 HDL0.91 ± 0.210.95 ± 0.260.93 ± 0.170.96 ± 0.19
Triglycerides (mmol/L)1.8 ± 0.81.9 ± 0.92.2 ± 1.12.4 ± 1.4
GFR (mL/min/1.73 m2)80 ± 2283 ± 1886 ± 2590 ± 21
  • Data are mean ± SD or percentages. Incident composite CVD events in the VADT included myocardial infarction; stroke; new or worsening congestive heart failure; surgical intervention for cardiac, cerebrovascular, or peripheral vascular disease; inoperable coronary artery disease; and amputation for ischemic gangrene. Incident composite CVD in the ACCORD included myocardial infarction, stroke, and cardiovascular death. GFR, glomerular filtration rate (Modification of Diet in Renal Disease formula).

  • *P < 0.05, †P < 0.01, ‡P < 0.001, §P < 0.0001, independent samples t test or χ2 test, as appropriate.